Category: Counterpoints
What Should Frontline Treatment Be in Chronic Myeloid Leukemia?
The US Food and Drug Administration has approved 3 tyrosine kinase inhibitors (TKIs) for use as frontline treatment in chronic myeloid leukemia (CML): imatinib, dasatinib (Sprycel, […]
Should Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Be Intensive?
Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Counterpoints: Approximately 20% to 30% of adults diagnosed with acute lymphoblastic leukemia are positive […]
What Should Standard Frontline Therapy Be in Older Patients With Chronic Lymphocytic Leukemia?
Clinical Advances in Hematology & Oncology Volume 14, Issue 5, May 2016 Jennifer A. Woyach, MD, vs Clemens-Martin Wendtner, MD Now that ibrutinib (Imbruvica, Pharmacyclics/Janssen), a […]
Should EGFR Tyrosine Kinase Inhibitors Be Used in Non–Small Cell Lung Cancer in the Absence of EGFR Mutations?
Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1 Tyrosine kinase inhibitors (TKIs) that block epidermal growth factor receptor (EGFR) clearly work […]
Should All Patients With SCLC Receive Prophylactic Cranial Irradiation If They Have Responded to Treatment?
Clinical Advances in Hematology & Oncology November 2015, Volume 13, Issue 11 Ben J. Slotman, MD, PhD vs Jacob Yousef, BS, and Henry Wagner, MD Brain […]
Is There a Clinical Role for Molecular Phenotyping in Atypical Presentation of Metastatic Castration-Resistant Prostate Cancer?
Now that our understanding of potentially actionable mutations has increased, is it time for physicians to look into molecular phenotyping for their patients with metastatic castration-resistant […]
Which Should Be Used First in Symptomatic Metastatic Castration-Resistant Prostate Cancer, Docetaxel or Radium?
Clinical Advances in Hematology & Oncology May 2015, Volume 13, Issue 5 It is not unusual for metastatic prostate cancer to progress despite treatment with abiraterone […]
Counterpoints: Do Patients With Multiple Myeloma Need Maintenance Treatment?
Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Multiple myeloma is an incurable disease, and patients who respond to treatment eventually […]
Counterpoints: Is Proton Beam Therapy Better Than Standard Radiation Therapy?
Clinical Advances in Hematology & oncology December 2014, Volume 12, Issue 12 Is Proton Beam Therapy Better Than Standard Radiation Therapy? Proton beam therapy has […]
Targeted Therapy vs Chemotherapy: Which Has Had More Impact on Survival in Lung Cancer?
Clinical Advances in Hematology & Oncology November 2014, Volume 12, Issue 11 Chemotherapy and targeted therapy both have earned their place in the treatment of lung […]
Should Lung Cancer Screening With Low-Dose Computed Tomography Be Routine for Smokers and Former Smokers?
Clinical Advances in Hematology & Oncology October 2014, Volume 12, Issue 10 The U.S. Preventive Services Task Force (USPSTF) gave a grade of B to low-dose […]
Is Maintenance Therapy Necessary in Low-Grade Lymphoma?
Clinical Advances in Hematology & Oncology August 2014, Volume 12, Issue 8 Maintenance therapy with rituximab has been shown to prolong progression-free survival and event-free survival in […]
Screening Mammography: Do the Benefits Always Outweigh the Harms?
Clinical Advances in Hematology & Oncology June 2014, Volume 12, Issue 6 “Mammography saved my life” is a common refrain from women who have been screened and […]
To Transplant or Not To Transplant in Multiple Myeloma
Clinical Advances in Hematology & Oncology May 2014, Volume 12, Issue 5 High-dose therapy in combination with autologous stem cell transplantation (ASCT) has become the standard […]
Counterpoints: Can Radiotherapy Be Omitted in Patients With Localized Hodgkin Lymphoma?
Clinical Advances in Hematology & Oncology April 2014, Volume 12, Issue 4 Radiation therapy has a dramatic effect on lymphomas, and has played an important role in […]
Why Are Cancer Drugs So Costly?
Clinical Advances in Hematology & Oncology January 2014, Volume 12, Issue 1 The cost of cancer drugs is at an all-time high, with several lifesaving agents costing […]